NCT06894576 Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis
| NCT ID | NCT06894576 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ottawa Hospital Research Institute |
| Condition | Cancer-associated Thrombosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2024-12-03 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2024-12-03 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study is to prospectively develop a risk assessment model (RAM) that accurately identifies anticoagulated cancer-associated thrombosis (CAT) patients at low- and high-risk of recurrent venous thromboembolism (VTE) and clinically relevant bleeding within 6 months following the CAT diagnosis and to create a biobank of plasma and whole blood samples for further translational research in cancer genetics and hemostasis.
Eligibility Criteria
Inclusion Criteria: * Objectively documented distal and/or proximal DVT of the limb (upper or lower extremity) and/or PE, splanchnic vein thrombosis and/or cerebral sinus vein thrombosis in presence of active cancer of all types * Intended treatment of CAT for at least 6 months with parenteral or oral anticoagulants at therapeutic dosing. * Estimated life expectancy \> 6 months * Willingness to give an informed consent * Age ≥ 18 years Exclusion Criteria: * Unusual site CAT (gonadal vein thrombosis, ovarian vein thrombosis, retinal vein thrombosis) * Superficial vein thrombosis * Refusal of informed consent \> 72 hrs of anticoagulants * Age \< 18 years old
Contact & Investigator
Marc Carrier, MD
PRINCIPAL INVESTIGATOR
Ottawa Hospital
Frequently Asked Questions
Who can join the NCT06894576 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer-associated Thrombosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06894576 currently recruiting?
Yes, NCT06894576 is actively recruiting participants. Contact the research team at kvrotniakaite@toh.ca for enrollment information.
Where is the NCT06894576 trial being conducted?
This trial is being conducted at Ottawa, Canada.
Who is sponsoring the NCT06894576 clinical trial?
NCT06894576 is sponsored by Ottawa Hospital Research Institute. The principal investigator is Marc Carrier, MD at Ottawa Hospital. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.